PALA (NSC-224131) in advanced carcinoma of the cervix. A phase II study of the Gynecologic Oncology Group

H. B. Muss, B. Bundy, P. J. DiSaia, Frederick Stehman, J. Beecham

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Thirty-six patients with advanced carcinoma of the cervix received PALA at a dosage of 5 gm/m2 every three weeks. Thirty-three patients had received prior irradiation therapy and chemotherapy. No complete or partial responses were seen. The major toxicity was determatologic and occurred in 16/36 (44%) of patients. Three patients experienced dose limiting disorientation or confusion. PALA was not associated with any antitumor activity in patients with advanced carcinoma of the cervix who had received prior chemotherapy. The results of this study indicate that PALA has no substantial activity in patients with advanced squamous carcinoma of the cervix who have previously received chemotherapy.

Original languageEnglish (US)
Pages (from-to)741-744
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume7
Issue number6
StatePublished - 1984
Externally publishedYes

Fingerprint

NSC 224131
Cervix Uteri
Carcinoma
Drug Therapy
Squamous Cell Carcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

PALA (NSC-224131) in advanced carcinoma of the cervix. A phase II study of the Gynecologic Oncology Group. / Muss, H. B.; Bundy, B.; DiSaia, P. J.; Stehman, Frederick; Beecham, J.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 7, No. 6, 1984, p. 741-744.

Research output: Contribution to journalArticle

@article{49bdf14d272d46de80a8912f4199c9c5,
title = "PALA (NSC-224131) in advanced carcinoma of the cervix. A phase II study of the Gynecologic Oncology Group",
abstract = "Thirty-six patients with advanced carcinoma of the cervix received PALA at a dosage of 5 gm/m2 every three weeks. Thirty-three patients had received prior irradiation therapy and chemotherapy. No complete or partial responses were seen. The major toxicity was determatologic and occurred in 16/36 (44{\%}) of patients. Three patients experienced dose limiting disorientation or confusion. PALA was not associated with any antitumor activity in patients with advanced carcinoma of the cervix who had received prior chemotherapy. The results of this study indicate that PALA has no substantial activity in patients with advanced squamous carcinoma of the cervix who have previously received chemotherapy.",
author = "Muss, {H. B.} and B. Bundy and DiSaia, {P. J.} and Frederick Stehman and J. Beecham",
year = "1984",
language = "English (US)",
volume = "7",
pages = "741--744",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - PALA (NSC-224131) in advanced carcinoma of the cervix. A phase II study of the Gynecologic Oncology Group

AU - Muss, H. B.

AU - Bundy, B.

AU - DiSaia, P. J.

AU - Stehman, Frederick

AU - Beecham, J.

PY - 1984

Y1 - 1984

N2 - Thirty-six patients with advanced carcinoma of the cervix received PALA at a dosage of 5 gm/m2 every three weeks. Thirty-three patients had received prior irradiation therapy and chemotherapy. No complete or partial responses were seen. The major toxicity was determatologic and occurred in 16/36 (44%) of patients. Three patients experienced dose limiting disorientation or confusion. PALA was not associated with any antitumor activity in patients with advanced carcinoma of the cervix who had received prior chemotherapy. The results of this study indicate that PALA has no substantial activity in patients with advanced squamous carcinoma of the cervix who have previously received chemotherapy.

AB - Thirty-six patients with advanced carcinoma of the cervix received PALA at a dosage of 5 gm/m2 every three weeks. Thirty-three patients had received prior irradiation therapy and chemotherapy. No complete or partial responses were seen. The major toxicity was determatologic and occurred in 16/36 (44%) of patients. Three patients experienced dose limiting disorientation or confusion. PALA was not associated with any antitumor activity in patients with advanced carcinoma of the cervix who had received prior chemotherapy. The results of this study indicate that PALA has no substantial activity in patients with advanced squamous carcinoma of the cervix who have previously received chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0021712456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021712456&partnerID=8YFLogxK

M3 - Article

C2 - 6528869

AN - SCOPUS:0021712456

VL - 7

SP - 741

EP - 744

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 6

ER -